Pharmacoepidemiologic Investigation of the Risk Factors Associated with Hypocalcemia Induced by Denosumab

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Japanese Journal of Pharmaceutical Health Care and Sciences

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.5649/JJPHCS.41.578
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure?

  2013cited by this paper
• Identification of the risk factors associated with hypocalcemia induced by denosumab.

  2013cited by this paper
• Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

  2012cited by this paper
• 57: A Single Dose Study of Denosumab in Patients With Various Degrees of Renal Impairment

  2010cited by this paper
• Adverse effects of proton pump inhibitors.

  2010cited by this paper
• Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series.

  2010cited by this paper
• A case series of proton pump inhibitor-induced hypomagnesemia.

  2010cited by this paper
• The Effect of Proton Pump-Inhibiting Drugs on Mineral Metabolism

  2009cited by this paper
• Revised equations for estimated GFR from serum creatinine in Japan.

  2009cited by this paper
• Hypomagnesaemia due to use of proton pump inhibitors--a review.

  2009cited by this paper
• Hypomagnesemia induced by several proton-pump inhibitors.

  2009cited by this paper
• Severe hypomagnesaemia in long‐term users of proton‐pump inhibitors

  2008cited by this paper
• Omeprazole and refractory hypomagnesaemia

  2008cited by this paper
• Effects of Esomeprazole on Acid Output in Patients With Zollinger-Ellison Syndrome or Idiopathic Gastric Acid Hypersecretion

  2007cited by this paper
• NCCN Task Force Report: Bone Health in Cancer Care.

  2006cited by this paper
• Long-term proton pump inhibitor therapy and risk of hip fracture.

  2006cited by this paper
• Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity

  2006cited by this paper
• Proton-pump inhibitors and hypomagnesemic hypoparathyroidism.

  2006cited by this paper
• The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.

  2005cited by this paper
• Recommendations for zoledronic acid treatment of patients with bone metastases.

  2005cited by this paper
• Toxic acute tubular necrosis following treatment with zoledronate (Zometa).

  2003cited by this paper
• Effect of L-lactic acid on calcium absorption in rats fed omeprazole.

  1998cited by this paper
• FUNCTIONAL HYPOPARATHYROIDISM AND PARATHYROID HORMONE END‐ORGAN RESISTANCE IN HUMAN MAGNESIUM DEFICIENCY

  1976cited by this paper
• Interpretation of Serum Calcium in Patients with Abnormal Serum Proteins

  1973cited by this paper

• No citing papers are available for this paper.